Global Rheumatoid Arthritis Competitor Landscape Report 2018-2019YE

News provided by

Feb 04, 2019, 13:30 ET

DUBLIN, Feb. 4, 2019 /PRNewswire/ --

The "Competitor Landscape: Rheumatoid Arthritis" report has been added to ResearchAndMarkets.com's offering.

"Competitor Landscape: Rheumatoid Arthritis", briefings contain evaluations of ongoing development activities within the Rheumatoid Arthritis (RA) disease market, together with analysis of current & potential future product positioning.

Key Highlights from the report

If the results of the Phase II MANTA safety trial are required by the FDA prior to filing for regulatory approval of filgotinib for Rheumatoid Arthritis (RA), this could delay US approval by 2 years.
Given that the Phase II NCT03241108 trial is limited to 90 patients in the EU, it is likely that NovImmune will need to initiate a second Phase II trial with a larger number of patients, including US patients, prior to proceeding with a Phase III program for NI-0101 in Rheumatoid Arthritis (RA).
The Phase II trial assessing the immunogenicity and safety of Zostavax in Rheumatoid Arthritis (RA) patients using abatacept, if positive, is likely to boost physician opinion of abatacept's safety profile in Rheumatoid Arthritis (RA), and reduce potential physician concerns that the use of abatacept may negatively impact the effectiveness of some immunizations, as suggested by its US FDA label.

Landscape Updates

Order of Entry' analysis, detailing timeline forecasts for each drug in Phase II development or higher.
Timeline forecasts for each approved product's lifecycle management initiatives.
Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies.

Pipeline Landscape

An overview of pipeline candidates, containing snapshots of current development status.
Expected drug-specific events & milestones until YE 2019.

Approved Product Landscape

An overview of pipeline candidates, containing snapshots of current development status.
Expected drug-specific events & milestones until YE 2019.

Appendix

Current early stage RA pipeline & candidate Watch List',
Timeline assumptions, including standard assumptions & drug-specific assumptions.

Scope

The briefing is based on Sociable Pharma's analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher - these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
Market Entry' & Direction of Travel' positioning analysis for pipeline & currently approved therapies is also provided.

Reasons to Buy

Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts.

Key Topics Covered:

Introduction to Sociable Pharma's Competitor Landscape'
Executive Summary
Key Events & Landscape Updates
Landscape Updates
Order of Entry
Key Competitor Market Entry Strategies
Lifecycle Development
Key Competitor Direction of Travel'
Pipeline Landscape
Pipeline Summary
Approved Product Development Landscape
Lifecycle Development
Appendix

Companies Mentioned

AbbVie
Abivax
Ablynx
ACEA Biosciences
Acerta Pharma
Akari Therapeutics
Akros Pharma
Amgen
Asana Biosciences
Astellas
AstraZeneca
Bayer
Biocad
Bird Rock Bio
BMS
Boehringer Ingelheim
Can-Fite Biopharma
Celgene
Chemo-Centryx
Cyclacel
Daichii Sankyo
Eddingpharm
Eisai
Galapagos
Genentech
Gilead
GSK
Hanmi
Hutchison Medi Pharma
Innate Pharma
Innocare Pharma
Istesso
Janssen
Japan Tobacco
Jiangsu HengRui
Lilly
Lupin
MacroGenics
MedImmune
Merck KGaA
Mesoblast
Momenta
MorphoSys
Morphotek
MSD
Nektar Therapeutics
Novartis
NovImmune
Noxopharm
Nuevolution
Oscotec
OSE Immuno Therapeutics
Pfizer
Philogen
Principia Biopharma
Protalex
Reata Pharmaceuticals
Regen BioPharma
Regeneron
Rigel Pharmaceuticals
Roche
Rottapharm Biotech
R-Pharm
Sanofi
Sareum
Swedish Orphan Biovitrum
Taiho
Taisho
Takeda
TiGenix
UCB
Valeant
Viela Bio
Vitaeris
WuXi
Xencor

For more information about this report visit https://www.researchandmarkets.com/research/v4q283/global_rheumatoid?w=5

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets